BidaskClub upgraded shares of Immunomedics (NASDAQ:IMMU) from a hold rating to a buy rating in a research note published on Friday morning.

A number of other research analysts have also weighed in on IMMU. Zacks Investment Research lowered Immunomedics from a buy rating to a hold rating in a research report on Wednesday, November 15th. ValuEngine lowered Immunomedics from a hold rating to a sell rating in a research report on Monday, December 4th. Finally, Jefferies Group raised their price objective on Immunomedics from $22.00 to $27.00 and gave the company a buy rating in a research report on Wednesday, January 24th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of Buy and an average target price of $19.00.

Immunomedics (NASDAQ:IMMU) opened at $15.13 on Friday. The firm has a market capitalization of $2,300.00, a PE ratio of -8.13 and a beta of 1.50. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 1.20. Immunomedics has a 12-month low of $4.63 and a 12-month high of $18.93.

In related news, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the completion of the transaction, the director now owns 99,178 shares in the company, valued at $1,179,226.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Behzad Aghazadeh purchased 1,325,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was bought at an average price of $10.47 per share, with a total value of $13,872,750.00. The disclosure for this purchase can be found here. Company insiders own 6.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtus Fund Advisers LLC purchased a new position in Immunomedics in the fourth quarter worth about $456,000. UBS Asset Management Americas Inc. boosted its position in shares of Immunomedics by 81.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 65,149 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 29,238 shares during the period. BlackRock Inc. boosted its position in shares of Immunomedics by 8.8% during the fourth quarter. BlackRock Inc. now owns 9,064,259 shares of the biopharmaceutical company’s stock valued at $146,478,000 after buying an additional 736,608 shares during the period. Wells Fargo & Company MN boosted its position in shares of Immunomedics by 32.0% during the fourth quarter. Wells Fargo & Company MN now owns 388,937 shares of the biopharmaceutical company’s stock valued at $6,285,000 after buying an additional 94,372 shares during the period. Finally, First Trust Advisors LP purchased a new position in shares of Immunomedics during the fourth quarter valued at approximately $2,248,000. Institutional investors own 75.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Immunomedics (IMMU) Raised to “Buy” at BidaskClub” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2018/02/13/immunomedics-immu-raised-to-buy-at-bidaskclub.html.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.